Fructose contributes to the Warburg effect for cancer growth.

Cancer Fructose Hypoxia Lactate Mitochondria Polyol pathway Uric acid

Journal

Cancer & metabolism
ISSN: 2049-3002
Titre abrégé: Cancer Metab
Pays: England
ID NLM: 101607582

Informations de publication

Date de publication:
2020
Historique:
received: 10 03 2020
accepted: 01 07 2020
entrez: 17 7 2020
pubmed: 17 7 2020
medline: 17 7 2020
Statut: epublish

Résumé

Obesity and metabolic syndrome are strongly associated with cancer, and these disorders may share a common mechanism. Recently, fructose has emerged as a driving force to develop obesity and metabolic syndrome. Thus, we assume that fructose may be the mechanism to explain why obesity and metabolic syndrome are linked with cancer. Clinical and experimental evidence showed that fructose intake was associated with cancer growth and that fructose transporters are upregulated in various malignant tumors. Interestingly, fructose metabolism can be driven under low oxygen conditions, accelerates glucose utilization, and exhibits distinct effects as compared to glucose, including production of uric acid and lactate as major byproducts. Fructose promotes the Warburg effect to preferentially downregulate mitochondrial respiration and increases aerobic glycolysis that may aid metastases that initially have low oxygen supply. In the process, uric acid may facilitate carcinogenesis by inhibiting the TCA cycle, stimulating cell proliferation by mitochondrial ROS, and blocking fatty acid oxidation. Lactate may also contribute to cancer growth by suppressing fat oxidation and inducing oncogene expression. The ability of fructose metabolism to directly stimulate the glycolytic pathway may have been protective for animals living with limited access to oxygen, but may be deleterious toward stimulating cancer growth and metastasis for humans in modern society. Blocking fructose metabolism may be a novel approach for the prevention and treatment of cancer.

Identifiants

pubmed: 32670573
doi: 10.1186/s40170-020-00222-9
pii: 222
pmc: PMC7350662
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

16

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK048520
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK108408
Pays : United States

Informations de copyright

© The Author(s) 2020.

Déclaration de conflit d'intérêts

Competing interestsMAL, DRT, LGL, CJR, and RJJ have equity in a start-up company developing fructokinase inhibitors (Colorado Research Partners LLC), and TN and RJJ also have equity with XORTX therapeutics which is developing novel xanthine oxidase inhibitors. All others declare no conflicts of interest.

Références

Biochem J. 1967 Sep;104(3):1040-7
pubmed: 6049856
Ann Emerg Med. 1986 Dec;15(12):1470-7
pubmed: 3777620
Biochim Biophys Acta. 1960 Jan 1;37:127-38
pubmed: 14401391
Nature. 1998 Sep 17;395(6699):284-8
pubmed: 9751057
Biochem J. 1970 Sep;119(3):501-10
pubmed: 5500310
Eur J Cancer. 1999 Jul;35(7):1076-82
pubmed: 10533451
J Am Soc Nephrol. 2020 May;31(5):898-906
pubmed: 32253274
J Physiol. 1949 Aug;109(1-2):98-102
pubmed: 15394310
Cell Metab. 2018 Feb 6;27(2):351-361.e3
pubmed: 29414685
Nat Commun. 2013;4:2434
pubmed: 24022321
J Gen Physiol. 1927 Mar 7;8(6):519-30
pubmed: 19872213
Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4320-5
pubmed: 22371574
Cancer Res. 1995 Mar 15;55(6):1373-8
pubmed: 7882338
Stroke. 1992 Nov;23(11):1617-22
pubmed: 1440710
Nat Clin Pract Nephrol. 2005 Dec;1(2):80-6
pubmed: 16932373
J Physiol. 1949 Mar 15;108(2):117-26
pubmed: 16991843
J Anim Sci. 1982 Jul;55(1):73-6
pubmed: 6181047
BMB Rep. 2018 Sep;51(9):429-436
pubmed: 30158026
Science. 1969 Jul 25;165(3891):402-3
pubmed: 5789437
Nature. 2020 Mar;579(7800):586-591
pubmed: 32214246
Diabetes. 1997 Feb;46(2):179-86
pubmed: 9000692
FEBS Lett. 1976 Sep 15;68(1):8-14
pubmed: 134909
Cell Metab. 2020 Jul 7;32(1):117-127.e3
pubmed: 32502381
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1298-1306
pubmed: 30031605
Brain Res. 2017 Feb 15;1657:312-322
pubmed: 28034722
Nat Rev Cancer. 2004 Nov;4(11):891-9
pubmed: 15516961
Kidney Int. 2014 Aug;86(2):294-302
pubmed: 24336030
Am J Med Sci. 1989 May;297(5):294-9
pubmed: 2719056
Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):138-47
pubmed: 15668487
J Clin Endocrinol Metab. 2005 Feb;90(2):1171-5
pubmed: 15562012
PLoS One. 2012;7(10):e47948
pubmed: 23112875
Science. 2017 Apr 21;356(6335):307-311
pubmed: 28428423
JAMA. 2019 Jan 22;321(3):256-265
pubmed: 30667502
Cell Metab. 2018 Jun 05;27(6):1249-1262.e4
pubmed: 29706565
Cell Metab. 2019 Oct 1;30(4):735-753.e4
pubmed: 31577934
Pancreas. 2009 Aug;38(6):706-12
pubmed: 19506535
Brain Res. 1990 May 21;516(2):310-2
pubmed: 2364296
Nat Commun. 2017 Feb 13;8:14181
pubmed: 28194018
Cancer Res. 1991 Jun 15;51(12):3316-22
pubmed: 2040005
Atherosclerosis. 2016 Oct;253:171-177
pubmed: 27451002
J Biol Chem. 2012 Nov 23;287(48):40732-44
pubmed: 23035112
J Cell Physiol. 2006 Jun;207(3):614-27
pubmed: 16523487
Nat Genet. 2011 Jul 31;43(9):869-74
pubmed: 21804546
Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2098-105
pubmed: 16172216
Nephrol Dial Transplant. 2012 Feb;27(2):608-12
pubmed: 21613382
Am J Clin Nutr. 2006 Nov;84(5):1171-6
pubmed: 17093171
PLoS One. 2008 Aug 13;3(8):e2915
pubmed: 18698340
Proc Natl Acad Sci U S A. 2010 May 11;107(19):8788-93
pubmed: 20421486
Cancer Res. 2011 Apr 1;71(7):2550-60
pubmed: 21300765
Nature. 2015 Jun 25;522(7557):444-449
pubmed: 26083752
Gastroenterology. 2017 Sep;153(3):743-752
pubmed: 28579536
Nat Cell Biol. 2016 May;18(5):561-71
pubmed: 27088854
Biochem J. 1960 Feb;74:216-23
pubmed: 13842495
Sports Med. 2017 Mar;47(Suppl 1):23-32
pubmed: 28332117
J Am Soc Nephrol. 2014 Nov;25(11):2526-38
pubmed: 24876114
Cancer Cell. 2016 Nov 14;30(5):779-791
pubmed: 27746145
Biochem Biophys Res Commun. 2018 Jun 2;500(2):462-469
pubmed: 29660339
Clin Biochem. 2010 Jan;43(1-2):198-207
pubmed: 19747474
J Clin Invest. 2018 Feb 1;128(2):545-555
pubmed: 29388924
Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):3138-3143
pubmed: 29507217
Biochem J. 2002 May 15;364(Pt 1):309-15
pubmed: 11988105
Nat Rev Cancer. 2004 Jun;4(6):437-47
pubmed: 15170446
Nutr Metab (Lond). 2012 Oct 02;9(1):89
pubmed: 23031075
Am J Physiol Renal Physiol. 2006 Mar;290(3):F625-31
pubmed: 16234313
J Clin Endocrinol Metab. 2019 Jul 1;104(7):3003-3011
pubmed: 30869790
Am J Physiol Renal Physiol. 2016 Oct 1;311(4):F722-F730
pubmed: 27465991
Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):349-53
pubmed: 11567808
Front Nutr. 2015 May 06;2:12
pubmed: 25988140
Carcinogenesis. 2017 Feb 1;38(2):119-133
pubmed: 27993896
J Natl Cancer Inst. 2003 Jun 18;95(12):914-6
pubmed: 12813175
Obesity (Silver Spring). 2016 Feb;24(2):453-60
pubmed: 26499447
Dev Cell. 2016 Mar 7;36(5):540-9
pubmed: 26954548
Nat Rev Microbiol. 2005 Jan;3(1):36-46
pubmed: 15608698
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7556-60
pubmed: 1502167
J Histochem Cytochem. 2009 Aug;57(8):763-74
pubmed: 19365088
Cancer Res. 2016 Jan 1;76(1):24-9
pubmed: 26729790
Med Sci Monit. 2006 Dec;12(12):CR525-529
pubmed: 17136009
Science. 1956 Aug 10;124(3215):269-70
pubmed: 13351639
Cancer Res. 2010 Aug 1;70(15):6368-76
pubmed: 20647326
Am J Physiol. 1992 Sep;263(3 Pt 1):G312-8
pubmed: 1384349
Science. 2019 Mar 22;363(6433):1345-1349
pubmed: 30898933
Int J Oncol. 2010 Sep;37(3):615-22
pubmed: 20664930
Biochem J. 1997 Jan 1;321 ( Pt 1):239-46
pubmed: 9003425
J Clin Invest. 1969 Mar;48(3):574-83
pubmed: 5773093
Cell. 2012 Apr 27;149(3):656-70
pubmed: 22541435
Br J Cancer. 1955 Dec;9(4):539-49
pubmed: 13304213
FASEB J. 1994 Apr 1;8(6):414-9
pubmed: 8168691
Cell Death Dis. 2018 May 10;9(5):557
pubmed: 29748554
Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):E1619-28
pubmed: 22623530
Bioconjug Chem. 2007 May-Jun;18(3):628-34
pubmed: 17444608
Diabetes. 1998 Jun;47(6):867-73
pubmed: 9604861
J Natl Cancer Inst. 2002 Sep 4;94(17):1293-300
pubmed: 12208894
J Clin Invest. 1978 Oct;62(4):721-6
pubmed: 701471
Science. 1968 Sep 20;161(3847):1253-4
pubmed: 5673437
J Cell Physiol. 2007 May;211(2):477-85
pubmed: 17167776
J Intern Med. 2020 Mar;287(3):252-262
pubmed: 31621967
Am J Kidney Dis. 2002 Sep;40(3):464-71
pubmed: 12200796
Am J Physiol. 1987 Sep;253(3 Pt 1):G390-6
pubmed: 3631273
Biochem J. 1993 Dec 15;296 ( Pt 3):785-96
pubmed: 8280078
Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1847-52
pubmed: 8700847
FASEB J. 2002 Feb;16(2):243-5
pubmed: 11772943
Am J Clin Nutr. 2010 Nov;92(5):1071-9
pubmed: 20826630
Nucl Med Biol. 2011 May;38(4):461-75
pubmed: 21531283
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683
J Intern Med. 2017 Aug;282(2):202-204
pubmed: 28646607

Auteurs

Takahiko Nakagawa (T)

Department of Nephrology, Rakuwakai Otowa Hospital, 2 Otowa-Chinji-cho, Yamashina-ku, Kyoto, Japan.
Department of Stem Cell Biology & Regenerative Medicine, Shiga University of Medical Science, Otsu, Japan.

Miguel A Lanaspa (MA)

Division of Renal Diseases and Hypertension, University of Colorado Denver, Aurora, CO USA.

Inigo San Millan (IS)

Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado School of Medicine, Aurora, USA.

Mehdi Fini (M)

University of Colorado Cancer Center, Aurora, CO USA.

Christopher J Rivard (CJ)

Department of Medical Oncology, University of Colorado Denver, Aurora, CO USA.

Laura G Sanchez-Lozada (LG)

Department of Cardio-Renal Physiopathology, Instituto Nacional de Cardiología Ignacio Chavez, 14080 Mexico City, CP Mexico.

Ana Andres-Hernando (A)

Division of Renal Diseases and Hypertension, University of Colorado Denver, Aurora, CO USA.

Dean R Tolan (DR)

Department of Biology, Boston University, Boston, MA USA.

Richard J Johnson (RJ)

Division of Renal Diseases and Hypertension, University of Colorado Denver, Aurora, CO USA.

Classifications MeSH